Report of Foreign Issuer (6-k)
March 26 2019 - 4:32PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
March 25, 2019
001-36686
(Commission file number)
Forward Pharma A/S
(Translation of registrant’s name
into English)
Østergade 24A, 1st Floor
1100 Copenhagen K, Denmark
(Address of principal executive office)
________________________________________
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes [ ] No [ X ]
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes [ ] No [ X ]
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934. Yes [ ] No [ X ]
If “Yes” is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): N/A
|
Item 1.
|
Receipt of Notice from Biogen
|
On March 25, 2019, Forward Pharma A/S (the “Company”)
received notice from the two wholly owned subsidiaries of Biogen Inc. (“Biogen”) party to the Settlement and License
Agreement with the Company, dated January 17, 2017 (the “License Agreement”), of their exercise of the option to purchase
the intellectual property in the U.S. associated with the Company pursuant to the License Agreement. The Company and Biogen have
consummated the assignment of the U.S. intellectual property to Biogen upon the execution of assignment agreements and the payment
of a nominal amount by Biogen to FWP IP ApS, and Biogen has assumed ownership and responsibility for the assigned U.S. intellectual
property.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: March 26, 2019
|
Forward Pharma A/S
|
|
|
|
|
|
By:
|
/s/ Claus Bo Svendsen
|
|
|
|
Name: Claus Bo Svendsen
|
|
|
Title: Chief Executive Officer
|
Forward Pharma AS (NASDAQ:FWP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Forward Pharma AS (NASDAQ:FWP)
Historical Stock Chart
From Apr 2023 to Apr 2024